25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
Markets started 2020 witnessing the detrimental impact of the COVID-19 pandemic on the global econom...
Read More >
2019 was an interesting year, especially politically and legally. Yet Indonesia has made it to 2020 ...
Read More >
The National Labor Relations Board (“NLRB”) recently announced changes to its representation case ...
Read More >
COVID-19 (commonly known as the coronavirus) has now spread to the premerger antitrust review proces...
Read More >
Special Edition Week In Review: Read all about it! While many of you were at holiday over the last ...
Read More >
What does it feel like winning the lottery? I don’t know but it has to feel a lot like getting pick...
Read More >